Endothelin Antagonism and Its Role in the Treatment of Hypertension

Rebecca C Moorhouse, David J Webb, David C Kluth, Neeraj Dhaun

Research output: Contribution to journalArticlepeer-review


Hypertension contributes greatly to global disease burden and in many patients current treatments do not adequately control blood pressure (BP). Endothelin-1 (ET-1) is a potent vasoconstrictor that is implicated in the pathogenesis of hypertension, including the hypertension that is often associated with chronic kidney disease (CKD) and the metabolic syndrome. ET receptor antagonists, currently licensed for the treatment of pulmonary arterial hypertension and scleroderma-related digital ulcers, are being investigated for the treatment of hypertension. Clinical trials have addressed the use of ET receptor antagonists as monotherapy in primary hypertension, as an add-on therapy in resistant hypertension and in CKD. This review will evaluate the current evidence regarding the therapeutic potential of ET receptor antagonists in hypertension, as well as highlighting important issues that still need to be addressed.
Original languageEnglish
Pages (from-to)489-496
Number of pages8
JournalCurrent Hypertension Reports
Issue number5
Publication statusPublished - Oct 2013


Dive into the research topics of 'Endothelin Antagonism and Its Role in the Treatment of Hypertension'. Together they form a unique fingerprint.

Cite this